Internal Med Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator
British Journal of Haematology, 07/13/07

Harmatz, P., et al. – For iron chelation, weekly treatment with starch-conjugated deferoxamine (S-DFO), a high-molecular-weight iron chelator with prolonged vascular retention, has the potential to achieve iron balance in the poorly compliant patient.

Methods

IV infusion of S-DFO into groups of four transfusion-dependent patients with beta-thalassaemia at single doses of 150, 300, 600, 900 mg/kg
Evaluation of urinary iron excretion and pharmacologic parameters for 1 week and of safety for 3 weeks

Results

No drug-related effects were observed on clinical chemistries, hematological and coagulation parameters, urinalyses, vital signs, or ECGs
Drug-related adverse events were limited to four urticarial reactions, none requiring infusion termination
The drug stimulated clinically significant urinary iron excretion; the 900-mg dose induced iron excretion of 1.31 mg/kg over 1 week with residual iron-biding capacity in plasma for >6 days

<< Previous
Influenza and Pneumococcal Vaccine Coverages in Geriatric Health...

Next >>
Posterior pelvic floor disorders: a prospective comparison using...